55 related articles for article (PubMed ID: 33466490)
21. The difference in serum proteomes in schizophrenia and bipolar disorder.
Smirnova L; Seregin A; Boksha I; Dmitrieva E; Simutkin G; Kornetova E; Savushkina O; Letova A; Bokhan N; Ivanova S; Zgoda V
BMC Genomics; 2019 Jul; 20(Suppl 7):535. PubMed ID: 31291891
[TBL] [Abstract][Full Text] [Related]
22. Characterizing acyl-carnitine biosignatures for schizophrenia: a longitudinal pre- and post-treatment study.
Cao B; Wang D; Pan Z; Brietzke E; McIntyre RS; Musial N; Mansur RB; Subramanieapillai M; Zeng J; Huang N; Wang J
Transl Psychiatry; 2019 Jan; 9(1):19. PubMed ID: 30655505
[TBL] [Abstract][Full Text] [Related]
23. Metabolomics in patients with psychosis: A systematic review.
Li C; Wang A; Wang C; Ramamurthy J; Zhang E; Guadagno E; Trakadis Y
Am J Med Genet B Neuropsychiatr Genet; 2018 Sep; 177(6):580-588. PubMed ID: 30076730
[TBL] [Abstract][Full Text] [Related]
24. The MetaCyc database of metabolic pathways and enzymes.
Caspi R; Billington R; Fulcher CA; Keseler IM; Kothari A; Krummenacker M; Latendresse M; Midford PE; Ong Q; Ong WK; Paley S; Subhraveti P; Karp PD
Nucleic Acids Res; 2018 Jan; 46(D1):D633-D639. PubMed ID: 29059334
[TBL] [Abstract][Full Text] [Related]
25. Potential role of amino acids in pathogenesis of schizophrenia.
Saleem S; Shaukat F; Gul A; Arooj M; Malik A
Int J Health Sci (Qassim); 2017; 11(3):63-68. PubMed ID: 28936154
[TBL] [Abstract][Full Text] [Related]
26. Profiling of Acylcarnitines in First Episode Psychosis before and after Antipsychotic Treatment.
Kriisa K; Leppik L; Balõtšev R; Ottas A; Soomets U; Koido K; Volke V; Innos J; Haring L; Vasar E; Zilmer M
J Proteome Res; 2017 Oct; 16(10):3558-3566. PubMed ID: 28786289
[TBL] [Abstract][Full Text] [Related]
27. Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms.
Kantrowitz JT; Epstein ML; Lee M; Lehrfeld N; Nolan KA; Shope C; Petkova E; Silipo G; Javitt DC
Schizophr Res; 2018 Jan; 191():70-79. PubMed ID: 28318835
[TBL] [Abstract][Full Text] [Related]
28. Altered brain arginine metabolism in schizophrenia.
Liu P; Jing Y; Collie ND; Dean B; Bilkey DK; Zhang H
Transl Psychiatry; 2016 Aug; 6(8):e871. PubMed ID: 27529679
[TBL] [Abstract][Full Text] [Related]
29. A meta-analysis of placebo-controlled trials of omega-3 fatty acid augmentation in schizophrenia: Possible stage-specific effects.
Chen AT; Chibnall JT; Nasrallah HA
Ann Clin Psychiatry; 2015 Nov; 27(4):289-96. PubMed ID: 26554370
[TBL] [Abstract][Full Text] [Related]
30. An LC-MS/MS method to quantify acylcarnitine species including isomeric and odd-numbered forms in plasma and tissues.
Giesbertz P; Ecker J; Haag A; Spanier B; Daniel H
J Lipid Res; 2015 Oct; 56(10):2029-39. PubMed ID: 26239049
[TBL] [Abstract][Full Text] [Related]
31. Increased oxidative stress and oxidative DNA damage in non-remission schizophrenia patients.
Sertan Copoglu U; Virit O; Hanifi Kokacya M; Orkmez M; Bulbul F; Binnur Erbagci A; Semiz M; Alpak G; Unal A; Ari M; Savas HA
Psychiatry Res; 2015 Sep; 229(1-2):200-5. PubMed ID: 26213375
[TBL] [Abstract][Full Text] [Related]
32. Severe disturbance of glucose metabolism in peripheral blood mononuclear cells of schizophrenia patients: a targeted metabolomic study.
Liu ML; Zhang XT; Du XY; Fang Z; Liu Z; Xu Y; Zheng P; Xu XJ; Cheng PF; Huang T; Bai SJ; Zhao LB; Qi ZG; Shao WH; Xie P
J Transl Med; 2015 Jul; 13():226. PubMed ID: 26169624
[TBL] [Abstract][Full Text] [Related]
33. The Carnitine Palmitoyl Transferase (CPT) System and Possible Relevance for Neuropsychiatric and Neurological Conditions.
Virmani A; Pinto L; Bauermann O; Zerelli S; Diedenhofen A; Binienda ZK; Ali SF; van der Leij FR
Mol Neurobiol; 2015 Oct; 52(2):826-36. PubMed ID: 26041663
[TBL] [Abstract][Full Text] [Related]
34. An overview of diabetes management in schizophrenia patients: office based strategies for primary care practitioners and endocrinologists.
Annamalai A; Tek C
Int J Endocrinol; 2015; 2015():969182. PubMed ID: 25878665
[TBL] [Abstract][Full Text] [Related]
35. Mitochondrial dysfunction in schizophrenia: pathways, mechanisms and implications.
Rajasekaran A; Venkatasubramanian G; Berk M; Debnath M
Neurosci Biobehav Rev; 2015 Jan; 48():10-21. PubMed ID: 25446950
[TBL] [Abstract][Full Text] [Related]
36. Lipid peroxidation in psychiatric illness: overview of clinical evidence.
Joshi YB; Praticò D
Oxid Med Cell Longev; 2014; 2014():828702. PubMed ID: 24868318
[TBL] [Abstract][Full Text] [Related]
37. Similarities in serum acylcarnitine patterns in type 1 and type 2 diabetes mellitus and in metabolic syndrome.
Bene J; Márton M; Mohás M; Bagosi Z; Bujtor Z; Oroszlán T; Gasztonyi B; Wittmann I; Melegh B
Ann Nutr Metab; 2013; 62(1):80-5. PubMed ID: 23296094
[TBL] [Abstract][Full Text] [Related]
38. Schizophrenia shows a unique metabolomics signature in plasma.
He Y; Yu Z; Giegling I; Xie L; Hartmann AM; Prehn C; Adamski J; Kahn R; Li Y; Illig T; Wang-Sattler R; Rujescu D
Transl Psychiatry; 2012 Aug; 2(8):e149. PubMed ID: 22892715
[TBL] [Abstract][Full Text] [Related]
39. Novel, objective, multivariate biomarkers composed of plasma amino acid profiles for the diagnosis and assessment of inflammatory bowel disease.
Hisamatsu T; Okamoto S; Hashimoto M; Muramatsu T; Andou A; Uo M; Kitazume MT; Matsuoka K; Yajima T; Inoue N; Kanai T; Ogata H; Iwao Y; Yamakado M; Sakai R; Ono N; Ando T; Suzuki M; Hibi T
PLoS One; 2012; 7(1):e31131. PubMed ID: 22303484
[TBL] [Abstract][Full Text] [Related]
40. Neuroanatomical markers of genetic liability to psychosis and first episode psychosis: a voxelwise meta-analytical comparison.
Fusar-Poli P; Smieskova R; Serafini G; Politi P; Borgwardt S
World J Biol Psychiatry; 2014 Apr; 15(3):219-28. PubMed ID: 22283467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
